Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468983 | 0.84 | HTR2C (0.38) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL8169426 | 0.84 | RIPK1 (0.46) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL8160937 | 0.84 | MEN1 (0.40) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL16306919 | 0.83 | CACNA1G (0.35) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL13332070 | 0.82 | KDM4E (0.40) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL18186254 | 0.82 | HTR2C (0.38) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL8164937 | 0.82 | HTR2C (0.38) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL8169606 | 0.82 | SLC6A4 (0.42) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL17705197 | 0.81 | ITGA4 (0.43) | — | |
| SCHEMBL545286 | 0.81 | CACNA1G (0.47) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | CACNA1G 4553/4885CACNA1B 3944/4885CACNA1C 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.